Clopidogrel: A review of its mechanism of action

Platelets

Volumn 9, Issue 3-4, 1998, Pages 251-255

  Savi, P ^a   Nurden, P ^b   Nurden, A T ^b   Levy Toledano, S ^c   Herbert, J M ^a  

^a Haemobiology Research Department   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CALCIUM ION; CLOPIDOGREL; CYTOCHROME P450; TICLOPIDINE;

BINDING SITE; CALCIUM CELL LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MEMBRANE BINDING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE MEMBRANE;

ANIMALIA;

EID: 0031862658     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537109876799     Document Type: Conference Paper

References (20)

1. Herbert JM, Frehel D, Vallée E, Kieffer G, Gouy D, Berger Y, Necciari J, Defreyn G, Maffrand JP. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Res 1993; 11: 180-98.
2. CAPRIE Steering Comittee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348: 1329-39.
3. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassée, Combalbert, J, Defreyn G, Maffrand JP. Importance of hepatic metabolism for the anti-aggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992, 44(3): 527-32.
4. Savi P, Heilmann E, Nurden P, Laplace MC, Bihour C, Kieffer G, Nurden AT, Herbert JM. Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin Appl Thromb Hemostas 1996; 2, 35-42.
5. Mills DCB, Puri R, Hu C-J, Minniti C, Grana G, Freedman MD, Colman RF, Colman RW. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thrombos 1992; 12: 430-6.
6. 3H]2-methylthio ADP to rat platelets: effect of clopidogrel and ticlopidine. J Pharm Exp Ther 1994; 269: 772-7.
7. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital detect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 1992; 80: 2787-96.
8. Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, Nurden A. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J Clin Invest 1995; 95: 1612-22.
9. Savi P, Laplace MC, Herbert JM. Evidence for the existence of two different ADP-binding sites on rat platelets. Thromb Res 1994; 76: 157-69
10. Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA. Adenosine diphosphate in red cells is a factor in the adhesiveness of human blood platelets. Nature (Lond) 1961; 192: 531-2.
11. Humbert M, Nurden P, Bihour C, Pasquet J-M, Winckler J, Heilmann E, Savi P, Herbert J-M, Kunicki TJ, Nurden AT. Ultrastructural studies of platelet aggregates from human subjects recieving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet aggregation. Arteriocler Thromb Vasc Biol 1996; 16: 1532-43.
12. Defreyn G, Gachet C, Savi P, Driot F, Cazenave JP, Maffrand JP. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemostas 1991; 65: 186-90.
13. Gachet C, Cazenave JP, Ohlmann P, Bouloux C, Defreyn G, Driot F, Maffrand JP. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1. Biochem Pharmacol 1990; 40: 2683-7.
14. Gachet C, Savi P, Ohlmann P, Maffrand JP, Jakobs KH, Cazenave JP. ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes - an effect selectively blocked by the thienopyridine clopidogrel. Thromb Haemostas 1992; 68: 79-83.
15. Savi P, Pflieger AM, Herbert JM. cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coag Fibrinolysis 1996; 7: 249-52.
16. Savi P, Artcanuthurry V, Bornia J, Grelac F, Maclouf J, Levy-Toledano S, Herbert JM. Effect of clopidogrel treatment on ADP-induced phosphorylations in rat platelets. Br J Haematol 1997; 97: 185-91.
17. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thombasthenic slate in normal platelets following the administration of ticlopidine. J Clin Invest 1985; 75: 328-38.
18. Hardisty RM, Powling MJ, Nokes TJC. The action of ticlopidine on human platelets. Studies of aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemostas 1990; 64: 150-5.
19. Dunn FW, Soria J, Soria C, Thomaidis A, Lee H, Caen JP. In vivo effect of ticlopidine on fibrinogen-platelet cofactor activity and binding of fibrinogen to platelets. Agents Action Suppl 1 1984; 15: 97-104.
20. Gachet C, Stierlé A, Cazenave JP, Ohlmann P, Lanza F, Bouloux C, Maffrand JP. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol 1990; 40: 229-38.